Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Supportive and palliative care

3064 - Development of GOLD (Geriatric Oncology Liaison Development) service to improve outcomes in older people with cancer


28 Sep 2019


Poster Discussion – Supportive and palliative care


Matthaios Kapiris


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


M. Kapiris1, L. Karapanagiotou1, J.L. Mansi2, D. Harari2, T. Kalsi2, C. Pye2, R. Finch2, G. Babic-Illman2

Author affiliations

  • 1 Medical Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 2 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3064


The number of older people with cancer has been steadily increasing. Treating older people with anticancer treatments is challenging due to comorbidities, polypharmacy, poorer performance status and underrepresentation in clinical trials. An innovative service, GOLD, has been set up in our Cancer Centre. GOLD delivers comprehensive geriatric assessment (CGA) in older cancer patients to improve reversible factors and assist with anticancer treatment. We report outcomes of patients reviewed in GOLD clinic.


A one-stop GOLD clinic for older cancer patients was set up in 2016. From October 2016 to April 2018, 596 patients between 50-99 years old were reviewed. The majority (69.9%) were between 70-84 years. For the purpose of this analysis, a representative sample of 298 patients with similar characteristics (73% between 70-84 years) was selected; analysis included primary site of malignancy, treatment type and setting, referral reason and GOLD interventions. Cancer treatment outcomes were divided into patients who continued with planned treatment, and those who required other types of management.


Referrals to GOLD were predominantly from gastrointestinal (28.5%), urology oncology (26.1%) and haematology (13.7%); lung, gynaecology, skin and breast accounted for the remaining 31.7%. The majority (92.7%) had single GOLD reviews. The following treatments were given: systemic anti-cancer therapy (SACT) with chemotherapy (51.6%), hormone therapy (21.1%), immune checkpoint inhibitors (6.8%), chemo-radiotherapy (6.8%) or tyrosine kinase inhibitors (3.6%). Of the 298 patients, 218 (73.2%) were able to proceed with their planned oncology treatment following GOLD review, start or continue SACT. 12.4% were deemed unfit and continued with best supportive care, 0.3% were referred to other specialities. 14.1% of the patients were on surveillance post anticancer treatment.


Collaborative working of oncologists with geriatricians may benefit older cancer patients with co-morbidities and age-specific problems. GOLD was largely “one-stop” and avoided multiple speciality referrals which may support cost-effectiveness whilst delivering more comprehensive care for older people with cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


MacMillan Cancer Support.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.